CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$51.78
+3.57%Next report
Analyst consensus
- Next report date
- Feb 11, 2027
- EPS estimate
- -$1.21
- Revenue estimate
- $10.7M
Latest reported
- Last report date
- Nov 2, 2026
- EPS actual
- -$1.15
- EPS estimate
- -$1.04
- Revenue actual
- $12.7M
- Revenue estimate
- $14.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -3.8%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $75
- PT range
- $52 – $90
- Analysts
- 5
3 Buy2 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 2, 2026 | -$1.04 | -$1.15 | Miss -10.58% | $12.7M |
| Aug 3, 2026 | -$1.19 | -$0.94 | Beat 21.01% | $10.2M |
| May 4, 2026 | -$1.20 | -$1.28 | Miss -6.57% | $1.5M |
| Feb 12, 2026 | -$1.15 | -$1.37 | Miss -19.13% | $864.0K |
| Feb 21, 2024 | -$0.07 | $1.10 | Beat 1671.43% | $200.0M |
| Feb 21, 2023 | -$2.32 | -$1.41 | Beat 39.22% | $6.0K |
| Nov 1, 2022 | -$2.30 | -$2.24 | Beat 2.61% | $94.0K |
| Feb 15, 2022 | -$1.74 | -$1.84 | Miss -5.75% | $12.3M |
| Nov 3, 2021 | -$1.69 | -$1.67 | Beat 1.18% | $329.0K |
| Jul 29, 2021 | $3.52 | $9.44 | Beat 168.18% | $900.2M |
| Feb 16, 2021 | -$1.23 | -$1.50 | Miss -21.95% | $194.0K |
| Oct 28, 2020 | -$1.17 | -$1.32 | Miss -12.82% | $148.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 11, 2027